Credit rating agency, ICRA has reaffirmed the A1+ rating assigned to the Rs 15.0 crore Commercial Paper (CP) / Short Term Debt (STD) programme of Unichem Laboratories.
The rating reaffirmation takes into account the company’s established presence in the domestic formulation business with sizeable exposure towards the fast growing and relatively high margin chronic therapeutic segments.
Unichem Laboratories is engaged in manufacturing formulations, pharmaceuticals and APIs. The company offers products in therapeutic areas like gastro-intestinal, cardiovascular, diabetes, psychiatry, neurology, anti-bacterial, anti-infective and pain management, among others.
